Comparison of Voice Therapy and Antireflex Therapy in LPR
Status:
Withdrawn
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This study will be a prospective, randomized, unblinded but controlled trial. Patients
presenting to the Otolaryngology clinic who are diagnosed with laryngopharyngeal reflux
disorder related dysphonia and meet inclusion criteria will be eligible to enroll in the
study. Subjects will be randomized to one of three treatment arms, voice therapy, anti-reflux
therapy, or a combination of voice therapy and anti-reflux therapy. Reflux symptom index
(RSI) scores, reflux finding scores (RFS), voice handicap index-10 (VHI-10) scores, and
consensus auditory perceptual evaluation-voice (CAPE-V) scores will be compared prior to
initiation of therapy as well as at 1, 2, and 3 months following initiation of treatment.